Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

So even a billion-dollar-or-so swing in Zepbound's future sales ... Additionally, Lilly could leverage specialty pharmacies or direct-to-patient models to bypass some PBM restrictions.

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Novo Nordisk said it had been able to ease some of the restrictions ... Earlier this week, Lilly raised its earnings forecasts as well, on the back of rising sales of Zepbound and diabetes therapy ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

Eli Lilly is working on a new drug, orforglipron, an oral tablet taken once daily, with no dietary restrictions ... Eli Lilly's total sales between Mounjaro and Zepbound were slightly under ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Novo Nordisk has been ceding market share to Eli Lilly, even though Zepbound's dollar sales still trail Wegovy ... the body and doesn't require dietary restrictions like oral semaglutide does ...

Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979). Zepbound ... between our sales teams and authors ...

For now, sales of Lilly’s injectable drugs with tirzepatide are driving the company’s growth. In the first quarter of 2025, Mounjaro had $3.84 billion in revenue and Zepbound $2.31 billion ...